All posts by imreal

The Society for Immunotherapy of Cancer to Hold Press Briefing on Nine Abstracts to be Presented at 37th Annual Meeting


News Image

The Society for Immunotherapy of Cancer (SITC) invites you to attend the virtual press briefing of the society’s 37th Annual Meeting (SITC 2022) beginning at 11:30 a.m. EST on Tuesday, Nov. 8, 2022.

The abstracts selected for the press briefing represent an array of the top advances in cancer immunotherapy research. Regular and late-breaking abstracts are embargoed until 8 a.m. EST, Nov. 7, 2022. Data shared during the presentation is embargoed until that date unless otherwise stated during the press briefing. For more information, please review the SITC 2022 Media Policy.

The presentations scheduled to occur during the press briefing are listed in order below:

Abstract #558: CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study

  • Presenter: Sumanta K. Pal, MD – City of Hope Comprehensive Cancer Center

Abstract #755: Results of a phase I trial of FT500, a first-in-class, off-the-shelf, iPSC derived NK cell therapy combined with PD-1/PD-L1 checkpoint blockade therapy and IL-2 in patients with advanced solid tumors

  • Presenter: Sandip P. Patel, MD – University of California, San Diego

Abstract #789: Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144-01 study)

  • Presenter: Amod A. Sarnaik, MD, FACS – H. Lee Moffitt Cancer Center

Abstract #568: Phase 2 trial of induction and concomitant CTLA4 (ipilimumab) and PD-1 (nivolumab) immune checkpoint blockade and intensity modulated radiation therapy (IMRT) in HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC)

  • Presenter: Maura L. Gillison, MD, PhD – The University of Texas MD Anderson Cancer Center

Abstract #605: Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

  • Presenter: Diwakar Davar, MD – University of Pittsburgh Medical Center Hillman Cancer Center

Abstract #614: Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients

  • Presenter: Saman Maleki, PhD – Western University, London, Canada

Abstract #711: Interim results of a phase 2 study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition

  • Presenter: Katherine M. Bever, MD – Johns Hopkins University


Abstract #1470: Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)

  • Presenter: Wade T. Iams, MD – Vanderbilt University Medical Center

Abstract #1478: A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells

  • Presenters: Stefanie Mandl, PhD – PACT Pharma


        Antoni Ribas, MD, PhD – University of California, Los Angeles

ADDITIONAL DETAILS:

Participating members of the media will have the opportunity to submit questions via chat for up to three minutes following each presentation. To attend this press briefing, you must register as a member of the press for SITC 2022. To register, please visit https://www.sitcancer.org/2022/press/press-registration. After registration is confirmed, you will receive instructions for the briefing. For more information regarding SITC 2022, please visit the Annual Meeting website at http://www.sitcancer.org/2022.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, and YouTube.

Share article on social media or email:



New WorldCat.org connects genealogy enthusiasts, educators, and historians to the world’s libraries


For genealogy enthusiasts, educators, and historians, the new WorldCat.org offers an improved experience to uncover family lineages and investigate historical events. By exploring the billions of library resources from more than 10,000 libraries worldwide represented on WorldCat.org, users can find an unparalleled pool of genealogical information.

“Genealogy research provides powerful and meaningful points of access into self-awareness and discovery of the world around us,” said Skip Prichard, President and CEO of OCLC, a global library nonprofit that’s been an innovator in library technology and research for more than 50 years. “WorldCat.org makes visible one of the most important research tools—the world’s libraries—making it a go-to source for detailed genealogical research.”

As more and more hobbyists and professionals alike seek to learn about the stories that precede and interweave with their own, WorldCat.org has a breadth and depth of information that can’t be found anywhere else online. Through WorldCat.org, people can identify a variety of source materials in libraries around the world, including:


  • Newspapers
  • Photographs
  • Family Bibles, church histories, and records
  • Cemetery and burial records
  • Military records
  • Town histories and probate records
  • General genealogical resources, such as directories, handbooks, and magazines
  • Slavery and antislavery materials, including slave records
  • Indexes of births, marriages, deaths, wills, and obituaries
  • Microfilmed genealogy and local history collections


FamilySearch has been working with OCLC to not only expand access to FamilySearch’s vast catalog of genealogically rich records from all over the globe, but to introduce FamilySearch patrons to WorldCat.org’s vast offerings online.

“FamilySearch.org users taking full advantage of all the resources of WorldCat.org may find many additional resources to enlighten their understanding of their ancestors. Many of these records tell the story of their lives between their birth and death. This is a valued, ongoing relationship with OCLC, and we will certainly encourage everyone from novices to experienced researchers to explore the depths of WorldCat.org’s resources,” said David E. Rencher, chief genealogy officer, FamilySearch International.

WorldCat.org is a unique tool for users to research heritage and complements genealogy tools such as FamilySearch, Ancestry.com, and other genealogy research tools.

“Libraries are often the only source for local information about births, deaths, marriages, businesses, and other family histories.

WorldCat.org can be the bridge to uncovering this valuable genealogy information,” concluded Prichard.

To start exploring and to sign up for a WorldCat.org account, visit the site at http://www.worldcat.org.

About WorldCat.org

Since 2006, WorldCat.org has been the window to the collections and resources of more than 10,000 libraries in more than 100 countries around the world. WorldCat.org is a unique destination, representing the world’s largest library community on the web. WorldCat.org is an innovation of OCLC, a nonprofit global library organization that provides shared technology services, original research, and community programs to member libraries and the library community at large. OCLC, member libraries, publishers, and other partner organizations collaboratively maintain WorldCat.org. Explore WorldCat.org on the web.

About OCLC

OCLC is a nonprofit global library organization that provides shared technology services, original research, and community programs so that libraries can better fuel learning, research, and innovation. Through OCLC, member libraries cooperatively produce and maintain WorldCat, the most comprehensive global network of data about library collections and services. Libraries gain efficiencies through OCLC’s WorldShare, a complete set of library management applications and services built on an open, cloud-based platform. It is through collaboration and sharing of the world’s collected knowledge that libraries can help people find answers they need to solve problems. Together as OCLC, member libraries, staff, and partners make breakthroughs possible.

Share article on social media or email:

Brevi-T, a Joint Venture between InterOme and Avrok Biosciences Will Change the Way We Understand and Solve Society’s Most Urgent Problems


Brevi-T Logo

“We aim to support every individual, community, and global network with precision public health solutions.” – Corina Shtir, Ph.D., CEO at InterOme

Brevi-T, a joint venture between InterOme, a trailblazing digital health enterprise, and molecular laboratory innovator Avrok Biosciences, is tackling some of the world’s most daunting public health challenges, including infectious disease, substance abuse, and environmental contamination.

Brevi-T revolutionizes the detection, assessment, analysis, and management of public health risk factors to prevent the spread of epidemics. The innovative, end-to-end ecosystem, which includes consistent process management and analytics, delivers centralized, actionable data to inform decision-making that greatly improves practices, plans, and policies for the best possible individual and public health outcomes.

Brevit-T is the first-ever single source solution that combines cutting-edge field sampling and laboratory testing with advanced data analytics and accessible user-friendly software in an effortless framework for day-to-day use by individuals, communities, districts, and private and public institutions. The customizable dashboard features a user-friendly interface that virtually anyone can use.

This seamless integration of automated wastewater testing, individual testing (when desired), real-time data enrichment, advanced analytics, reporting, and alerts delivers rapid, accurate results on a number of risk factors including, but not limited to pathogens, drugs of abuse, and environmental contaminants

The system brings an unprecedented level of efficiency, accuracy, automation, and speed to testing, analysis, and reporting, and makes understanding and communicating results and action plans simple and easy. Additionally, enriched real-time demographic, health, and environmental data makes predictive analysis and modeling possible.

This in turn can be used to anticipate where the next disease outbreak may be coming from, monitor the prevalence of illicit drug use to provide better education and support, or stay ahead of potentially harmful environmental conditions that may impact the health of the local community.

“Our goal is to solve general systemic problems through highly specialized approaches,” said Corina Shtir, Ph.D., CEO at InterOme. “Through our partnership with Avrok Biosciences, we escalated our impact exponentially by creating an ecosystem that allows us to shift epidemiology studies from retrospective to real-time monitoring, including prospective measures. We aim to support every individual, community, and global network with precision public health solutions.”

“Partnering with InterOme has been a natural fit from the very beginning,” said Jonathan Martin, COO at Avrok. “Their focus on public health, precision medicine, and passion for empowering patients to be more involved with their health data complements Avrok’s mission to help the population at large to fight against epidemics through awareness and prevention.”

About Brevi-T:

Brevi-T is a joint venture between InterOme and Avrok Biosciences. Brevi-T’s mission is to make the world a healthier place, by creating the means to detect, assess, manage, and prevent public health risk factors and infectious disease global pandemics. Through this global collaboration, the company harnesses the best experience and expertise into a business and industry framework that focuses on harm reduction and keeping people as healthy as possible. Harm reduction improves health outcomes by using actionable data to inform and support the best possible individual and public health outcomes. For additional information, please visit https://brevitbio.com/

About InterOme, Inc:

InterOme Inc. aims to close the gaps that slow down health-related decision-making and develop solutions that accelerate health from the individual to the community. InterOme works collaboratively with the precision medicine and public health communities to improve outcomes and accelerate health outcomes via specialized solutions that are scalable, cost-effective, and time efficient. InterOme brings together a team of expert physicians, scientists, and software developers with experience building enterprise-class solutions for private, public, and hybrid customers. For additional information, please visit https://interome.com/.

About Avrok Biosciences:

Avrok Biosciences is a CAP/CLIA-accredited molecular laboratory. Avrok was founded by experts in genetic testing and research, with a team of industry experts with over 50 years of combined experience who have dedicated their careers to science and medicine; together they have over 50 years of experience in oncology, diagnostics, and drug testing. Avrok has extensive experience with molecular assay development utilizing quantitative real-time PCR, microarray, mass spectrometry, and NGS and is focused on translating research assays into CAP/CLIA compliant laboratory developed tests. For additional information, please visit https://avrokbio.com/.

Share article on social media or email:

Protect Me With 3+ contest submissions now open for NJ middle, high school students to raise vaccine awareness


Participation is a critical component of teaching students to be good citizens and health messengers among peers and family.

Calling all New Jersey middle and high school students! This year’s Protect Me With 3+ vaccine awareness contest is now open for poster and video submissions through Jan. 20, 2023.

To stimulate creativity through health education, this year’s Create. Educate. Vaccinate. contest seeks to motivate students to create posters and videos illustrating the importance of getting vaccinated to achieve the highest level of community protection. The goal is to use the power of students’ creativity to raise awareness of the importance of vaccines in protecting New Jerseyans’ health and encourage more students and teachers to participate statewide.

“This year’s revitalized contest seeks to not only increase and diversify contest submissions but empower adolescents and educators to join in the fun to improve community health through vaccine awareness,” said Mariekarl Vilceus-Talty, MA, BSN, President & CEO of the Partnership for Maternal and Child Health of Northern New Jersey (PMCH). “Participation is a critical component of teaching students to be good citizens and health messengers among peers and family.”

Students in grades 5–12 are encouraged to design an 8.5×11 poster (by hand or digitally) or create a :30 video for an opportunity to win a $50-$300 Visa gift card. Artwork must feature educational information about one of the following vaccines: COVID-19; Tetanus, Diphtheria, Pertussis (Tdap); Human Papillomavirus (HPV); Meningococcal ACWY; and Flu. Full details and examples of past winners’ artwork are available at protectmewith3.com.

Vaccines play a vital role in keeping New Jersey communities healthy. They are the safest and most effective tools to help prevent serious symptoms and complications. The Centers for Disease Control and Prevention recommends vaccinations from birth through adulthood to provide a lifetime of protection against many diseases and infections.

“Vaccine-preventable diseases can affect anyone, regardless of age or health status, including healthy teens. Young and healthy people are not immune to serious illnesses,” said Dr. Christina Tan, New Jersey Department of Health (DOH) Assistant Commissioner and State Epidemiologist. “The best time to get vaccinated is before exposure to dangerous diseases. This contest helps inspire the next generation of artists and educators to contribute their creative talents to educate their communities.”

Digital entries can be submitted here. Hand-drawn posters can be mailed to:

The Partnership for Maternal and Child Health of Northern New Jersey

50 Park Place

Suite 700

Newark, NJ 07102

Middle school prizes

Poster

  • 1st place: $125
  • 2nd place: $75
  • 3rd place: $50

Video

  • 1st: $250
  • 2nd: $150
  • 3rd: $100

High school prizes

Poster

  • 1st place: $125
  • 2nd place: $75
  • 3rd place: $50

Video

  • 1st: $300
  • 2nd: $200
  • 3rd: $100

Three teachers whose classes submit the most submissions will win $75 each. Submissions entered before Jan. 6, 2023 will be eligible for an early bird prize of $50. Three early bird winners will be randomly selected. Finalists will be selected in March 2023, and an award celebration will be held in May to honor winners and participants.

The Protect Me With 3+ contest is a collaboration between PMCH and DOH.

Share article on social media or email:

UC Davis Health’s Melissa Jost Earns 2022 Stoltenberg Future Fund Health IT Leadership Scholarship


“My true passion is to use my background in EHR development and implementation, clinician wellbeing, and healthcare operations to advance the care we provide through our nation’s healthcare systems,” Jost said.

Stoltenberg Consulting Inc., a leading healthcare IT consulting firm, today named Melissa Jost, who serves as both the Director of Informatics and Director of Clinician Health and Wellbeing at UC Davis Health, as the recipient of the 2022 Stoltenberg Future Fund Scholarship for College of Healthcare Information Management Executives (CHIME) education.

The Stoltenberg Future Fund awards scholarships annually through the CHIME Education Foundation for recipient use at any of CHIME’s events, including the Healthcare CIO Boot Camp, CISO Boot Camp, Clinical Informatics Boot Camp, Fall CIO Forum and ViVE Conference. By supporting emerging health IT leaders, the scholarship channels industry-leading best practices for digital health advancement and interoperability into hospitals and health systems, enabling them to optimize IT systems for cross continuum care alignment. Scholarship demand has risen as pandemic recovery financial concerns have forced many hospital IT departments to cut funding for user group meetings, conferences and continuing education opportunities.

“CHIME has provided valuable mentorship and connections with leaders around the nation facing similar challenges, who I frequently rely on to develop new ideas and share lessons learned. The CHIME community has taught me not only how to address the challenges of health IT usability, adoption, and change management, but also how to become a better clinical informatics leader,” Jost said. “The gracious gift from Stoltenberg Consulting will allow me to further develop my leadership skills through CHIME to prepare for future leadership positions with UC Davis Health.”

As the inaugural Director of Clinical Informatics at UC Davis Health, Jost piloted and led the nationally-recognized Practice Experience Program (PEP) to reduce EHR burden and boost physician efficiency and satisfaction. Focusing on individually tailored EHR training, system optimization and workflow redesign, Jost deployed the PEP to over 1,800 physician faculty, residents and fellows, reducing physician time spent working after hours. She also oversaw the creation of a MyChart Message Response Team consisting of RNs, which manages 23,000 Primary Care messages per month across the UC Davis Health enterprise—improving turnaround time with 97% of messages being handled within 48 hours and reducing messages requiring physician intervention by 70%. Directly addressing the qualified IT staffing shortage plaguing healthcare, she also guided the creation of the Clinical Informatics Externship Program to provide a more diverse candidate pipeline into clinical informatics and health IT positions.

Prior to her current role, she served as a Senior Clinical Applications Analyst and Clinical Applications Project Manager at UC Davis Health, where she managed Epic implementation initiatives across all phases for revenue cycle, OR, anesthesia, patient access, radiology and referrals. She received the UC Davis Health Employee Excellence Team Award in 2020 and the STAR Award in 2019, along with the 2020 Josie King Hero Award. Jost plans to utilize the Stoltenberg Future Fund Scholarship toward her CHIME22 Fall Forum attendance in San Antonio.

Stoltenberg Consulting committed to hosting the annual CHIME Education Foundation scholarship over a span of 25 years. Jost is the 13th scholarship recipient of the Stoltenberg Future Fund program since its inception in 2009. To be eligible for this scholarship, applicants must be CHIME members in good standing, express need for financial support for continuing education and describe their professional accomplishments and aspirations in the healthcare IT industry. Previous recipients include IT leaders from Ascension Saint Thomas, Dayton Children’s Hospital, Texas Children’s Hospital, UNC Health Care, Brooke Army Medical Center, UPMC Chautauqua and Jackson Health System.

To learn more about the Stoltenberg Future Fund Scholarship, visit https://www2.stoltenberg.com/Scholarship.

About Stoltenberg Consulting

For over 27 years, Stoltenberg Consulting has exclusively served the healthcare industry by providing customizable IT support solutions. FlexSourcing, Stoltenberg Consulting’s three-time Best in KLAS Partial IT Outsourcing program, delivers day-one ROI through a versatile, certified health IT support workforce—including Tier 1+ help desk services—that can scale up at any time. Averaging 15 years of experience, Stoltenberg analysts are skilled in both financial and clinical systems with best practice expertise for Epic, Oracle Cerner, MEDITECH, NextGen, Allscripts and eClinicalWorks systems. To see how Stoltenberg simplifies healthcare technology, visit stoltenberg.com.

Share article on social media or email:

FitOn Health Launches Fall Prevention Program for Older Adults


News Image

FitOn, the No. 1 fitness app and digital health & wellness platform, today announced the launch of its Fall Prevention series on its FitOn Health platform for employers and health plans. Geared to help older adults take action to prevent falls from happening, this is the latest health course available for those looking to lead a healthier lifestyle without the need for expensive equipment or treatments.

Led by renowned fitness trainer and fall prevention specialist, David Jack, the program focuses on the necessary steps to avoid falls. This includes fall-proofing a home, learning balance and strength exercises and avoiding common mistakes that leave people vulnerable to falling. The course helps people to assess their risks, remove dangers inside and out of the home, overcome the stigma associated with falling and receive the support they need to enjoy life.

Every year, three million adults over 65 years old are treated in emergency departments for fall injuries that cost up to $50 billion in medical expenses annually, with 3/4 paid by Medicare and Medicaid. While not all falls are preventable, it is estimated that 20–30% of falls can be prevented by assessing risks and intervening to reduce these risks.

“Over 800,000 people are hospitalized annually due to falling and receiving a head injury or hip fracture. Such injuries can be costly to both patients and health insurers and a fear of falling begins to develop,” said Lindsay Cook, Founder and CEO of FitOn. “This fall prevention course empowers people to overcome this fear by assessing the risk, building up strength through functional exercises and taking steps to ensure their home is fall-proof. This course will also help members caring for aging parents by providing education and tips on how they can better communicate and mitigate fall related issues with aging loved ones”.

“Falls can lead to injuries, broken bones or even death and the fear of falling may cause a person to be less active in their everyday activities. In turn, they become weaker and their chances of falling increase,” says David Jack, course trainer of FitOn Health’s Fall Prevention program. “This course was developed with FitOn Health to focus on identifying a preventive process to help revive your body and significantly reduce the likelihood of falling.”

The expansion of FitOn Health’s course offerings comes off the heels of FitOn’s recent Peerfit acquisition earlier this year, which provides fitness and wellness benefits to employers and members nationwide through its deep relationship with leading health providers. Working in close partnership with its health plan partners, FitOn Health has introduced a range of care management courses on topics that address key areas of focus for plan members.

“Fall prevention is a big risk for individuals as they age and this program is an excellent resource to help seniors make changes to make their homes and keep themselves safe,” says Steven Selinsky, Vice President of Government Programs, Product, & Community Outreach for HAP, a current client that offers health insurance plans for individuals, families, employer groups and Medicare and Medicaid members. “Courses like this one from FitOn Health are great because they are easily accessible, can be watched at the member’s convenience, have very useful content from industry experts and can be shared with caregivers. The FitOn platform along with the benefits Peerfit provides helps individuals have access to information, platforms and resources to meet their health and wellness needs and live an active lifestyle.”

The Fall Prevention course includes 13 lessons and is immediately available to anyone with access to FitOn Health through their health plan or employer.

For more information, visit: https://web.fitonapp.com/course/fall-prevention

About FitOn Health

FitOn Health provides employers and health plans with FitOn’s premium digital fitness and hybrid health experiences to support the wellbeing of their employees, members and businesses. FitOn Health provides the tools for organizations to drive best-in-class engagement and measure the success of the program. It’s a one-stop wellness solution that can help your employees and members get more active, connect with coworkers, friends and family, and make leading a healthy lifestyle fun and motivating. Learn more at: https://health.fitonapp.com

For more information, please contact: press@fitonapp.com

Share article on social media or email:

Labrador Systems Announces First Business Customers of its Award-Winning Personal Assistive Robots


“The burden on caregivers is growing at a rate that is simply not sustainable. Organizations are already experiencing major caregiver shortages, and in the coming years there will be significantly more people 85+ with fewer people to help take care of them,” Mike Dooley, CEO of Labrador Systems.

Labrador Systems today announced the first reservations for the initial production of its assistive robots from several leading organizations in home care and senior living. First announced in January at CES 2022, the award-winning Labrador® Retriever personal robot empowers people to live more independently and extends the impact of caregivers. The assistive robot lightens the load of daily activities by physically bringing essential items within reach. Labrador will offer home care and senior living organizations a professional grade version of the robot, the “Retriever Pro,” with additional features to help caregivers and staff manage client care.

Labrador will make the Retriever Pro available as a service, creating fleets of robots for care providers to deploy to support individuals in a variety of settings. Organizations set to receive the first deliveries of the Retriever Pro include: On Lok PACE, Nationwide Insurance, Masonic Homes of California, Western Homes Communities, Eskaton, The Perfect Companion, Presbyterian Villages of Michigan, University of Michigan Flint, and Graceworks Lutheran Services.

The Retriever is the first autonomous robot of its kind to be deployed in homes at this scale to physically assist individuals with a range of daily activities.

The reservations follow Labrador’s groundbreaking series of pilot studies, where the company’s personal assistive robots were successfully deployed in the homes of a diverse mix of individuals with different needs and conditions. A video with testimonials from the initial pilot users is viewable at https://youtu.be/aTOyXBr9VyU.

“Our partnership with Labrador during the pilot enabled Nationwide to observe firsthand the impact the Retriever can have on individuals’ daily lives,” said Bobbi Jo Allan, Nationwide’s Vice President of Innovation. “As champions for helping people live as independently as possible, we’re excited at the prospect of continuing to learn alongside Labrador Systems about how best to support independent living. We look forward to deploying our own small number of robots to focus even more deeply on innovative ways we can provide value to our customers.”

“Labrador is at the forefront of creating an entirely new category of assistive robots.” added Micah Fening, Innovation Director at Nationwide. “We haven’t seen any other personal robot for the home with the Retriever’s capabilities.”

The Retriever Pro is designed to assist individuals where pain, injury or other health conditions impact their daily activities. It is large enough to carry items such as a laundry basket but agile enough to navigate the tight spaces of a home. The Retriever Pro also features an innovative retrieval and delivery system to bring items within reach, enabling caregivers to set up items for delivery when they are not present. Caregivers and users can easily command the Retriever Pro using their smartphone or with their voice through an Alexa-enabled device.

“The burden on caregivers is growing at a rate that is simply not sustainable. Organizations are already experiencing major caregiver shortages, and in the coming years there will be significantly more people in my parents’ age group (85+) with fewer people to help take care of them,” said Mike Dooley, CEO of Labrador Systems. “Our mission is to provide relief on both sides of that equation, empowering individuals who need care to do more on their own while extending the impact of each caregiver’s visit well beyond the time they are physically present.”

Labrador Charter Customers

To validate the product and gather feedback on the Retriever, Labrador worked with a range of organizations to place pilot robots into homes for real-world testing.

One such organization, On Lok, was founded 50 years ago in San Francisco as a nonprofit to empower older adults to age with dignity and independence. The organization pioneered PACE, the Medicare- and Medicaid-funded Program of All-Inclusive Care for the Elderly, which enables nursing home-eligible seniors to continue to live in their home and receive care and support in their own community.

“On Lok is excited to be one of the first healthcare organizations to bring the Retriever Pro into homes and continue to pioneer the future of care,” said Michael Webb, Chief Technology Officer at On Lok. “We are continuously looking for opportunities to enhance the support we provide to seniors and provide excellent quality of care to help them age with dignity. Labrador offers unique new ways to help us do this, and support our On Lok PACE participants, as well as assist our caregivers.”

Labrador’s pilots included tests and site visits with senior living communities, such as Masonic Homes of California, established in 1898.

“Our on-campus test of Labrador robots created quite an impression, generating excitement among our community,” said James MacRae, Innovation Project Manager of Masonic Homes CA. “We are eager to deploy our own fleet of Labrador Retriever Pros because it supports our mission to provide best-in-class experiences for our residents while allowing our caregivers to deliver high-touch personal care.”

With the announcement of the reservations for the Retriever Pro, the company also continues to move forward with development and testing of the standard version of the Retriever announced earlier this year.

###

About Labrador Systems, Inc.

Labrador Systems is an early-stage robotics company developing a new generation of assistive robots to help individuals live more independently and extend the impact of caregivers. The company’s core focus is creating affordable solutions that address practical and physical needs at a fraction of the cost of commercial robots. Labrador Systems’ investors include SOSV/HAX, Amazon’s Alexa Fund, iRobot Ventures, Grep VC and SkyRiver Ventures. Labrador was awarded a National Science Foundation Phase I SBIR Grant in 2021 and a Joseph F. Engelberger Foundation Robotics Grant for Elder Care in 2022. For more information, visit

http://www.labradorsystems.com.

Share article on social media or email:

PetMeds® Celebrates Senior Pets With “Fur-ever Young” Giveaway


News Image

“While nobody likes to think about their pet getting older, the senior years are a truly special time,” says Larissa Schenck, Director of Marketing at PetMeds®. “Cats and dogs become more settled down, more relaxed, and ready to enjoy an even deeper bond with their favorite humans.”

November is Senior Pet Month, dedicated to raising awareness of the perks of adopting a senior cat or dog as well as the importance of proper care and an active lifestyle to extend their happy, healthy years.

While every pet ages differently, a cat is generally considered a senior by the time they are ten years old. Dogs enter their senior years between five and ten years old, with smaller breeds aging more slowly than large dogs.

Over the past forty years, the average life expectancies of cats and dogs have nearly doubled. Pets are living longer due to higher standards in care and nutrition and advancements in veterinary science. It is not unusual for senior cats and dogs to live to celebrate their tenth, fifteenth, and even twentieth birthdays.

To keep middle-aged and senior pets in their best health for as long as possible, proper veterinary care is essential. Annual or twice-yearly wellness visits can catch illness early. Early intervention can be highly beneficial for common conditions seen in senior pets including kidney disease, diabetes, dental disease, and osteoarthritis.

Most cats and dogs will develop osteoarthritis in at least one joint in their lifetime. Pet parents can prevent or slow the progression by giving joint supplements at any age. For pets with osteoarthritis there are many effective pain management options including physical therapy, medications, holistic remedies, laser therapy, and acupuncture, making it possible for cats and dogs to stay active, healthy, and comfortable throughout their senior years.

“While nobody likes to think about their pet getting older, the senior years are a truly special time,” says Larissa Schenck, Director of Marketing at PetMeds®. “Cats and dogs become more settled down, more relaxed, and ready to enjoy an even deeper bond with their favorite humans.”

PetMeds® is celebrating senior pets by giving away Special Senior Support Prizes Packs containing Vetoquinol Pill Wraps, NaturVet Digestive Enzymes Plus Probiotic Powder, and HomeoPet Anxiety Relief every Friday in November. Dog prize packs will also include Zesty Paws Senior Advanced 11-in-1 Bites, and Cat prize packs will also include Soft VitaChews for Cats. All pet parents are invited to enter the “Fur-ever Young” giveaway at https://bit.ly/furreveryoung

The giveaway runs from November 2, 2022, through November 30, 2022. Everyone who enters from 12:01 AM Eastern Time (“ET”) November 2, 2022, to November 30, 2022, at 11:59 PM ET is eligible to win a cat or dog care pack. One cat and one dog winner will be chosen each week for a total of eight (8) winners.

ABOUT PETMEDS

Founded in 1996, Petmeds.com is Your Trusted Pet Health Expert, providing fast, easy and helpful service to over 10 million customers across North America. PetMeds® delivers prescription and non-prescription medications and pet supplies for less, direct to the consumer through its PetMeds® toll-free number, on the Internet through its website Petmeds.com, or with the PetMeds® free mobile app available for Apple and Android devices.

Share article on social media or email:

Biotechnology Innovators Honored in 2022 BioTech Breakthrough Awards Program


News Image

It’s an exciting time in the industry and we are thrilled to highlight the ‘breakthrough’ biotechnology solutions, services and companies around the world for our 2022 program – Bryan Vaughn, Managing Director of BioTech Breakthrough Awards

BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, today announced the results of the second annual BioTech Breakthrough Awards program. The winning BioTech Breakthrough selections for 2022 showcase life sciences and biotechnology companies that push ingenuity and exemplify the best in biotech solutions across the globe.

The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today. This year’s program attracted more than 1,350 nominations from over 12 different countries throughout the world. Categories include: BioPharma, Genomics, Therapeutics, Food Science, Immunology, BioServices and more.

“Advances in biological sciences, combined with accelerating development of computing, data processing, and AI are fueling a new wave of innovation in the healthcare sector. These advances are providing new understanding, new materials, new tools, as well as lower costs. We’re seeing trends in use of next-generation computing technology, growth in personalized treatment of rare diseases, vaccine development and the advancement of cell and gene therapies, to name a few,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “It’s an exciting time in the industry and we are thrilled to highlight the ‘breakthrough’ biotechnology solutions, services and companies around the world for our 2022 program. We extend our sincerest congratulations to our 2022 BioTech Breakthrough Award winners.”

The 2022 BioTech Breakthrough Awards program winners include:

BioPharma

Vaccine Innovation of the Year: Fast Track Automation, Honeywell

Overall BioPharma Solution of the Year: Scientist.com

Overall BioPharma Company of the Year: Boundless Bio

Genomics

Overall Genomics Innovation of the Year: Colossal Biosciences

Therapeutics

Therapeutics Solution of the Year: PharmaEssentia

Therapeutics Innovation of the Year: Cartography Biosciences

Diagnostics

Diagnostics Company of the Year: Longhorn

Immunology

Cancer Immunology Solution of the Year: Promontory Therapeutics

Overall Immunology Company of the Year: Ozette Technologies

Data & Analytics

Analytics Solution of the Year: Waters Corporation

Predictive Analytics Solution of the Year: VeriSIM Life

Analytics Solution Provider of the Year: Saama Technologies

Nutraceuticals

Nutraceutical Innovation of the Year: Brightseed

Medical Technology

Oncology Innovation of the Year: Imagene AI

MedTech Solution of the Year: Abbott

BioAgriculture

BioAg Breeding Solution of the Year: Dewey Scientific

Overall BioAgriculture Solution of the Year: C16 Biosciences

Overall BioAgriculture Company of the Year: Solis Agrosciences

BioInformatics

BioInformatics Company of the Year: Golden Helix

Industry Leadership

BioTech Company CEO of the Year: James Peyer, Ph.D., Cambrian Biopharma

BioTech Startup of the Year: Abata Therapeutics

BioTechnology Innovator of the Year: PTC Therapeutics

Overall BioTech Company of the Year: Vizgen

####

About BioTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughawards.com

Share article on social media or email:

Promontory Therapeutics Awarded “Cancer Immunology Solution of the Year” in 2022 BioTech Breakthrough Awards Program


News Image

We are grateful to BioTech Breakthrough for this award, which recognizes the importance of immunogenic small molecules in cancer care – Robert Fallon, Promontory President and Chief Executive Officer

Promontory Therapeutics Inc., a clinical stage biotech company advancing small molecule immunotherapies in oncology, today announced it has received the “Cancer Immunology Solution of the Year” award in the second annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Promontory Therapeutics is currently in Phase 2 clinical trials focused on the development of small molecule immunotherapy in cancer. Through its lead agent PT-112, the first ever conjugate of pyrophosphate in oncology, Promontory has realized advantages over the immune-oncology class of checkpoint inhibitors (CPIs) — including tolerability, pleiotropic mechanism of action, promotion of immunogenic cell death (ICD) and osteotropism (affinity to bone).

“We are grateful to BioTech Breakthrough for this award, which recognizes the importance of immunogenic small molecules in cancer care,” said Promontory President and Chief Executive Officer Robert Fallon. “Many patients do not respond to I-O checkpoint inhibitors, especially in solid tumors like late stage prostate cancer. Our drug candidate helps ignite the adaptive immune system and promotes clonal expansion of T-cells that lead to more durable therapeutic response.”

“ICD is a process that elicits an anti-cancer immune response related to the way in which a cancer cell dies. The induction of ICD is akin to viral mimicry and can be a critical factor in longer term response to therapy, whether alone or in combination with other immunotherapy agents,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “Based upon preclinical models, PT-112 represents the potential best-in-class ICD inducing agent. PT-112’s immunogenic cell death induction makes it a promising future treatment option in several possible cancer indications including thymoma and lung cancers. Congratulations on this true breakthrough and being our choice for ‘Cancer Immunology Solution of the Year.’”

In three completed Phase 1 trials, PT-112 demonstrated single-agent anti-cancer activity and safety. The company is currently enrolling patients in multiple Phase 2 trials, including a late-stage metastatic castration-resistant prostate cancer study, a disease with limited treatment options that has yet to see widespread approval of immunotherapies. In 2022, PT-112’s ICD effects in human and animal tumors were further validated in peer-reviewed articles in both the Lancet’s eClinical Medicine and MDPI’s Cancers.

PT-112 also exhibits a unique property, osteotropism, making it a strong candidate for treating cancers that originate in or metastasize to the bone, such as prostate cancer and hematological malignancies. A Phase 1 study in multiple myeloma was recently completed, an indication in which PT-112 holds orphan drug status.

In collaboration with the National Cancer Institute, PT-112 monotherapy is being studied in thymoma and thymic carcinoma, a rare disease with no approved FDA therapy for which PT-112 has also received orphan drug designation. Promontory also has an ongoing collaboration with Pfizer and Merck KGaA studying PT-112 in combination with PD-L1 checkpoint inhibitor, avelumab, in non-small cell lung cancer (NSCLC).

The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today. This year’s program attracted more than 1,350 nominations from over 12 different countries throughout the world.

####

About Promontory Therapeutics

Promontory Therapeutics Inc. is a privately held, clinical stage pharmaceutical company focused on small molecule immunotherapy. The company’s lead candidate, PT-112, is the first small molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to pattern recognition receptors on dendritic cells and promote the adaptive immune response in the tumor microenvironment. Clinical data generated across three Phase 1 studies have demonstrated single-agent anti-cancer activity and an attractive tolerability profile, and three Phase 2 studies of PT-112 are underway. The company’s research and development work has been conducted in the United States, Europe and Asia, along with a sub-license agreement for the development, commercialization and use of PT-112 in Greater China. The company also sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada), and has an active Phase 2 trial underway with the NCI utilizing PT-112 in thymic epithelial tumors where PT-112 has received Orphan Drug designation.

To learn more about Promontory Therapeutics, visit the company’s website here.

About BioTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughawards.com

Share article on social media or email: